Celularity Inc. has entered into definitive agreements to grant an exclusive license for its placental‑derived biomaterials portfolio and certain development‑stage programs as part of a strategic commercialization partnership, according to the company. The transaction is expected to close by April 15, 2026, subject to customary conditions, and could generate up to $35 million in upfront and milestone‑based payments, representing non‑dilutive capital for the company.
Under the terms, Celularity retains exclusive manufacturing rights for the licensed products at its FDA‑compliant facility in Florham Park, New Jersey, which the company claims will ensure ongoing manufacturing revenue and participation in the economics of future net sales for certain development‑stage products. The company will also be eligible to receive royalties once products reach commercialization.
As part of the transaction, personnel involved in commercial and product development biomaterials activities are expected to transition to the commercial partner at closing. The company states it will further reduce its workforce to lower operating expenses and align resources with its longevity‑focused therapeutic pipeline and manufacturing initiatives.
Celularity says the strategic deal allows it to monetize its commercial biomaterials portfolio and strengthen its capital position, enabling a sharper focus on developing placental‑derived cell therapies targeting biological drivers of aging, including cellular senescence, chronic inflammation and tissue degeneration.
